korecyte bio

Korecyte Bio (www.korecyte.com) is a biotech startup company, founded in **2023** in Maastricht, NL with a research site in London, UK

The expert team behind the next-gen ‘decision making’ cellular immunotherapy:

MANAGEMENT

CSO

James Arnold
Dphil, Associate Professor

- Reader (Associate Professor) at King’s College London
- Founder of King’s Tumour Immunology Group (KCL, UK)

CEO

Léon Spijkers
PhD

- 20+ yr in Life Sciences and pharma R&D, MT & BD.
- Founder Clouvance, Co-founder Sublin BV

CFO

Negotiations with a seasoned CFO

Expert CFO with 25+ yr of Financial experience in both private and public sectors within a.o. Life sciences.

COO

Negotiations with a seasoned COO

Seasoned expert in cell therapy from ideation to market. Former cell therapy director at big pharma.

ADVISORS

Onco trialist

Dr. Debs Sarker

Industry Expert

Dr. Ton Rijnders

Industry Expert

Dr. John Maher

Medical expert

Prof. J. Anderson

10 million

Each year 10 million patients die from cancer worldwide, despite all currently available therapies!

Immuno-oncology, especially CAR-T, could be a game-changer.

CAR-T therapy has been successful against blood cancers.

However, so far, no CAR-T immunotherapy has been proven successful against solid tumours, which has the highest incidence

The problem: barriers to traditional CAR-T approaches for solid tumour treatment.

The need: CAR-T biotechnology needs to be re-engineered to be effective in solid tumours.

OUR SOLUTION:
HypoxiCAR – a dual-oxygen sensing safety switch (platform technology)



HRE: only promotes CAR expression when in hypoxic tumour core - "ON"

ODD: destroy the CAR when in healthy tissue - "OFF"

CAR can target broad antigens (e.g. pan-protein family)

Hypoxia is a common characteristic of most solid tumours

PATENT PENDING

KING'S College LONDON

HypoxiCAR - enables succesful treatment of solid tumours

Traditional CARs

- Cannot dose high enough
- Severe toxicity risks
- Exhaustion weakens killing
- One unique target is difficult
- Suppressive TME (hypoxia)

HypoxiCAR

- **Inactive** in healthy tissue, so signficantly higher cell numbers can be safely infused
- Only **active** in the tumour, no prior tonic signaling: avoids CAR-T exhaustion
- Because of tumour-selectivity, broad targets can be used: no antigen escape
- Resistant to the suppressive effects of hypoxia: retain high killing capacity



HypoxiCAR – safe and effective

HypoxiCAR is SAFE



Mice survive even a very toxic CAR if combined with HypoxiCAR



No cytokine release (cytokine storm risk) in healthy mice exposed to HypoxiCAR.

HypoxiCAR is EFFICACIOUS



Human Head & neck tumours in mice are eradicated by HypoxiCAR

Product-development & commercialisation

internal

	discovery	lead	clin. candidate	PhI	PhII	PhIII	launch	
KOR 101			●					HNSCC
KOR-201		●						Orphan disease
Platform		●						Armoured HypoxiCAR
Platform	●							Allogenic HypoxiCAR
Platform	●							HypoxiCAR-γδT

partnered

Third Party CAR-based cell therapy

- Armoured CARs
- Risky targets (e.g. mesothelin)
- Different cell types
- Non-oncological diseases

Co-development activities caried out with the partner.
Any CAR construct and cell type is amenable to HypoxiCAR and for various disease areas (oncology, regenerative med, etc.)



CAR-T immunotherapy is a booming growth market

- Large multibillion market size which is vastly growing
- 1st indication: recurrent metastatic HNSCC, represents a huge medical need with a future SAM of $ 5 bln

  → 24 CAR-T programs running against HNSCC, but not with our dual-oxygen sensing CAR.

- HypoxiCAR can become a leading switching construct for various CARs

Global CAR-T market size



GlobalData reported forecasts

HypoxiCAR-T against HNSCC





Korecyte Bio Business plan

Corporate-development strategy

2023 - 2025
Preclinical phase

- *Team growth*
- *Preclinical package:*
- *Manufacturing (CDMO)*
- *Clinical design (CRO)*

2025-2026
Clinical proof (FIH)

- *CDMO FIH batches*
- *FIH against HNSCC*
- *R&D and BD expansion*
- **Reaching clinical validation is #1 priority**
- **Funding need € 18 Mio** (syndication details tbd)

2027 - 2028
Growth phase

- *Multiple programs in development*
- *Intensive BD*



2028 - beyond
Scale-up phase

- *Multiple clinical programs*

Korecyte's business model is based on:
- co-development & co-marketing with large pharmaceutical partners
- (sub)licensing to other CAR developers in non-competing Tas

Join us

...to get to the core of revolutionary therapies for current and future generations, together!

korecyte bio